Related Experiment Video
Updated: Apr 8, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral
Zhenxi Wang1,2,3, Weikun Huang1,2, Rasmus S Rasmussen4
1School of Medicine, College of Health, Adelaide University, Adelaide, Australia.
Aims:
Glucose-dependent insulinotropic polypeptide (GIP) may exert both insulinotropic and glucagonotropic effects. While its insulinotropic action is reportedly attenuated or abolished with worsening of glycaemic control in type 2 diabetes (T2D), the relationship between GIP and glucagon secretion across different levels of glycaemic control remains unclear. This study evaluated the relationship between postprandial GIP and glucagon responses to a mixed meal in T2D and to intraduodenal fat and glucose infusion in healthy and/or T2D individuals.
Materials And Methods:
Data were analysed from three clinical studies: mixed-meal testing in T2D (n = 79), intraduodenal fat infusion (2 kcal/min over 120 min) in T2D (n = 15) and intraduodenal glucose infusion (2 kcal/min over 60 min) in health and T2D (n = 10 each). Relationships between postprandial GIP and glucagon or insulin following the mixed meal were also determined after stratification by HbA1c (< 6.5%, 6.5%-7.0%, > 7.0%).
Results:
Following mixed-meal ingestion, early postprandial (0-30 min) glucagon secretion correlated positively with GIP, with the strength of this association increasing with higher HbA1c levels. In contrast, the insulinogenic index correlated with GIP only in subgroups with HbA1c < 6.5% and between 6.5%-7.0%. During intraduodenal fat infusion, glucagon and GIP responses correlated strongly in T2D. Following intraduodenal glucose infusion, early glucagon and GIP increments (0-15 min) were closely related in T2D, but not in healthy individuals.
Conclusions:
These observations indicate a glycaemia-dependent shift in endogenous GIP action in T2D, characterised by attenuation of insulinotropic effects and relative amplification of glucagonotropic effects with deteriorating glycaemic control.
Trial Registration:
ACTRN12614001131640, ACTRN12614001117606 and ACTRN12615001240538.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Hypoglycemia and Glucagon
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Glinides

